US Dollar vs Yen

登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。

ホーム
投資
株式
アメリカ
USOTC
PolyPeptide Group AG (PK) (PLYGF) 銘柄情報

PolyPeptide Group AG (PK) (PLYGF)

50.00

0.00

(0.00%)

終了 6月10日 5:00AM

PolyPeptide Group AG (PK) (PLYGF) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

50.00

( - )

買値

0.0101

売値

2,048.38

出来高

-

0.00 日の範囲 0.00

31.50 52 週間の範囲 50.00

時価総額

前日終値

50.00

始値

-

時刻

最終取引時間

財務取引量

-

VWAP

-

平均取引量 (3 か月)

US$ 85,086

発行済株式数

33,006,565

配当利回り

PER

-61.83

1 株当たり利益 (EPS)

-0.64

歳入

389.33M

純利益

-21.17M

PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally. It develops and manufactures synthetic peptides used as active pharmaceutical ingredients or intermediates in therapeutic products. The company offers po... PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally. It develops and manufactures synthetic peptides used as active pharmaceutical ingredients or intermediates in therapeutic products. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices, as well as development and analytical services. The company serves academic, pharmaceutical, and biotech companies. PolyPeptide Group AG was founded in 1952 and is headquartered in Baar, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V. 詳細を表示

セクター

-

業界

-

ウェブサイト

www.polypeptide.com

本社

Baar, Switzerland

設立

2026

PolyPeptide Group AG (PK) is listed in the sector of the その他OTC with ticker PLYGF. The last closing price for PolyPeptide (PK) was US$50. Over the last year, PolyPeptide (PK) shares have traded in a share price range of US$ 31.50 to US$ 50.00.

PolyPeptide (PK) currently has 33,006,565 shares in issue. The market capitalisation of PolyPeptide (PK) is US$1.65 billion. PolyPeptide (PK) has a price to earnings ratio (PE ratio) of -61.83.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	50	50	50	200	50	CS
12	14.61	41.2828482622	35.39	50	35.39	125	40.68223744	CS
26	15.75	45.9854014599	34.25	50	31.5	180	39.18311781	CS
52	15.75	45.9854014599	34.25	50	31.5	128	38.29962227	CS
156	15.75	45.9854014599	34.25	50	31.5	128	38.29962227	CS
260	15.75	45.9854014599	34.25	50	31.5	128	38.29962227	CS

PLYGF - Frequently Asked Questions (FAQ)

What is the current PolyPeptide Group AG (PK) share price?

The current share price of PolyPeptide Group AG (PK) is US$ 50.00

How many PolyPeptide Group AG (PK) shares are in issue?

PolyPeptide Group AG (PK) has 33,006,565 shares in issue

What is the market cap of PolyPeptide Group AG (PK)?

The market capitalisation of PolyPeptide Group AG (PK) is USD 1.65B

What is the 1 year trading range for PolyPeptide Group AG (PK) share price?

PolyPeptide Group AG (PK) has traded in the range of US$ 31.50 to US$ 50.00 during the past year

What is the PE ratio of PolyPeptide Group AG (PK)?

The price to earnings ratio of PolyPeptide Group AG (PK) is -61.83

What is the cash to sales ratio of PolyPeptide Group AG (PK)?

The cash to sales ratio of PolyPeptide Group AG (PK) is 3.36

What is the registered address of PolyPeptide Group AG (PK)?

The registered address for PolyPeptide Group AG (PK) is Neuhofstrasse 24, Baar, Zug, 6340

What is the PolyPeptide Group AG (PK) website address?

The website address for PolyPeptide Group AG (PK) is www.polypeptide.com

I-Glow

You never read any filings and here are the facts.
I suspected he was pushed out, and the SEC filings completely validate that.
?Castellum (NYSE-American: CTM) filed an 8-K stating that Wright "resigned" effective December 31, 2025. While corporate PR always uses the standard "no disp

Toronto_Trader

Toronto_Trader 10分前

The OTCM data is messed up. The ~149M unrestricted common shares were posted on December 9/25 and the 20M restricted common shares were posted Feb 25/26. No share issuance has occured since.

The exception being the 200M for the Kendrick deal, due to close within the next 3 weeks and s

Flip it

Flip it 11分前

You know your technology, no question about it.

Very clear

shajandr

shajandr 18分前

"He would be way too young for that."
Dude ... dude ... George was 66 years old. That is nott "way too young to die".

CANCER CHARLIE was 60 when he stopped circulating hemoglobin-containing envelopes, and he lived seven (7) years after diagnosis. His widowed wife is 61 and has

Helter Skelter

Helter Skelter 19分前

AI Overview 👉️ Yes, Malikie keeps its first $200 million in gross recoveries, and BlackBerry (BB) only begins receiving a percentage of the profits after Malikie is "made whole".

What date did these 4 settlements happen?

AI

rcbindustry

rcbindustry 19分前

The sentiment around AVXL seems extremely negative right now, which is often when biotech stocks become the most interesting to watch. There are still plenty of unanswered questions, but I think the next meaningful update from management will be more important than the daily share price fluctuations

wildwertski

wildwertski 22分前

The changes look good, but are simply cosmetic. It’s still the same app it was before. Still waiting for the most basic problems to be fixed. I guess we’ll just have to wait and see. Hope he comes through and something good happens. Best to all,WW

MartinLutherKing

MartinLutherKing 22分前

Oh Hell Yes something is brewing alright, Let’s all hold hands and pray for news$$$

100lbStriper

100lbStriper 25分前

i called it would break 30mil short, now it looks like they want 40mil.......anything really significant comes out and this will sky rocket!!!

Uncleteddy

Uncleteddy 27分前

You also forgot to mention that it is highly speculated that Talisman Group (hedge fund) created and used SPV to acquire more than the 71% of TGLO that delfin already owns. Which leads everyone to believe the float is much smaller than it appears on the surface

cottonisking

cottonisking 28分前

⏰️🐎🐎🐎 How has a recent Supreme Court ruling shifted SEC disgorgement powers in a bankruptcy case? The June 2026 Supreme Court ruling as it relates to LBHI's bankruptcy.

The U.S. Supreme Court did not rule on a case combining both Securities and Exchange Commiss

Moneysign5

Moneysign5 29分前

Not gonna lie. I have mixed emotions about this haha

chas1

WHY DOES IT NOT LOOK LIKE WINNING ?

MarcoPolo4

MarcoPolo4 32分前

You can’t do anything to stop someone from using your patents until they have a product introduced into the marketplace. You have to prove infringement of patents regarding material structure, manufacture or usage. You can’t do that until a finished product is sold and used by a customer. Usually a

Viking61

Viking61 35分前

It’s been violated since the Net Worth Sweep.

ace65

Less than a month ago we were in the trips..so we have had traction.
Looks like it basing here for next leg up.

nwtf

Only thing suppressing trades is the lack of investors. Wake up.

Checksinthemail

Checksinthemail 37分前

Hera gives the FHFA one mission as conservator, and that is preserved and conserv and make solvent. Once that is completed the FHFA director‘s job is complete and the company should be released The companies are no longer independent and insulated from the president political reasoning if they have

jour_trader

jour_trader 42分前

Completely agree on the intrinsic. Waiting game simply gets old. Few weeks away from next cc.

rich2

someone posted "Rich" might chime in

I KNOW WHAT I OWN, A chance for a grand slam home run from a little stinky pinky mining stock about to explode

anxiously awaiting the next news release

Moe2001

Moe2001 50分前

Which chrome Microsoft chrome 🤣? Ahh you think your words are useful lmaoo . BCAP LETS MAKE HISTORY 📈💥💨

mrwrn2010

mrwrn2010 51分前

“You realize we’ve dropped like 20% on what equates to 0.0005% of total shares per trading sessions.”

Bingo. What I’ve also been thinking about today is this - we just got acceptance of the ANDA filing for Eliquis. The price jumped after the announcement on slightly more volume but ha

dewophile

dewophile 56分前

Gsk retained some R and D in oncology and notably retained what became belantamab. I wonder if GSK gets back into oncology if belantamab didn’t show such promise (yet to be realized commercially). I feel like they bought tesaro to get some critical mass in oncology bc having just one drug launch is

jennybuystheblock

jennybuystheblock 56分前

Customers Bank... so close but so far away.

PolyPeptide (PK)

OMX Copenhagen Construct...

Hexagon Composites ASA

Flt Rte Nts 17/05/28

Teikoku Electric Manufac... (PK)

1.8750% until 11.02.2028

Titan Machinery

Telkom Indonesia Persero...

Foresight Enterprise VCT

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。